Furthermore, knockdown of PLCG2 potentiated the efficacy of anti-PD-1 therapy for CRC, and targeted inhibition of PLCG2 in combination with ICB therapy might confer better immunotherapy response and afford CRC patients the potential for survival advantages. Here, PDCD1 is linked to colorectal carcinoma.